Recent therapeutic advancements for advanced gastric cancer have been made through the integration of immunotherapy and chemotherapy, particularly for patients with negative human epidermal growth factor receptor 2 (HER2) status and positive programmed death ligand 1 (PD-L1) expression. Here, ERBB2 is linked to gastric cancer.